Sickle cell anaemia: current therapies.

Area of Science:

• Hematology
• Pediatric Hematology
• Genetic Blood Disorders

Background:

• Sickle cell anaemia (SCA) is a debilitating inherited blood disorder with significant morbidity and mortality.
• Advances in treatment have improved outcomes, but challenges remain in managing complications and expanding therapeutic options.

Purpose of the Study:

• To review current therapeutic strategies for sickle cell anaemia.
• To highlight the benefits of early intervention and established treatments.
• To discuss future directions for improving hematopoietic stem cell transplantation.

Main Methods:

• Literature review of recent advancements in sickle cell anaemia management.
• Emphasis on established therapies including hydroxyurea, blood transfusions, and iron chelation.
• Discussion of hematopoietic stem cell transplantation and its limitations.

Main Results:

• Early hydroxyurea therapy demonstrates significant clinical benefits for SCA patients.
• Blood transfusions coupled with iron chelation are crucial for managing SCA complications.
• Hematopoietic stem cell transplantation offers a curative option but requires further optimization.

Conclusions:

• Current treatment paradigms for sickle cell anaemia have evolved, offering improved quality of life.
• Further research into less toxic conditioning regimens and alternative donor sources is essential to expand access to hematopoietic stem cell transplantation.
• A multidisciplinary approach is key to optimizing care for individuals with sickle cell anaemia.